orforglipron vs semaglutide

orforglipron (S-tier) vs semaglutide (S-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

orforglipron · tier S

foundayo. the first non-peptide small-molecule oral GLP-1 receptor agonist. a once-daily pill, no injection, FDA-approved april 2026 for chronic weight management.

a small molecule, not a peptide. the first non-peptide oral GLP-1 receptor agonist to reach FDA approval. eli lilly's once-daily pill, sold as foundayo.

~12.4% ATTAIN-1 wt loss · half-life supports once-daily oral dosing per the FDA-approved label; small-molecule oral absorption without the food/water restrictions of oral peptide GLP-1s · weight loss

semaglutide · tier S

A GLP-1 receptor agonist with current US injection and oral products for distinct labeled uses.

Strong obesity, cardiovascular, kidney, and MASH evidence, but each result belongs to its own product, route, population, and label.

14.9% STEP 1 mean weight change · half-life ~1 week · weight loss

at a glance

• orforglipron: tier S · ~12.4% ATTAIN-1 wt loss
• semaglutide: tier S · 14.9% STEP 1 mean weight change

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.